Profile cover photo
Profile photo
Northwest Biotherapeutics
24 followers -
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.

24 followers
About
Northwest Biotherapeutics's posts

Post has attachment
Northwest Bio today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015.

Dr. Bosch will discuss new and emerging information from the Phase I trial of DCVax-Direct in regard to ongoing patient survival and factors associated with such survival. The poster is entitled “Cytokine Production by Human Dendritic Cells When Administered Intratumorally Correlates with Clinical Outcome in Subjects with Advanced Cancers.” This poster presentation will be presented in the 6:45 to 8:45 pm (EDT) Session A on Wednesday, September 16, 2015. Learn more in this release: http://ow.ly/Sii17

The Poster and the accompanying presentation will be posted on the NW Bio website following the presentation at nwbio.com/webcast. There will be no live webcast of the presentation.

Post has attachment
Northwest Biotherapeutics (NWBO) CEO Linda Powers will present at the SMi 4th Annual Cancer Vaccines Conference in London on Wednesday, September 16, 2015 at the Marriott Hotel, Regents Park.
Ms. Powers will present an update on the Company's clinical trial programs at 1:30 p.m. BST (8:30 a.m. US EDT).

In addition, Ms. Powers will participate in a panel discussion entitled "Where Is The Future For Cancer Vaccines?" chaired by Professor Farzin Farzaneh, Chairman of Molecular Medicine at King's College in London, and joined by Dr. Ravi Madan of the National Cancer Institute, at 4:40 p.m. BST.

Check out this press release for more information: http://ow.ly/SbPY2

And don’t forget you can tune in live to watch Ms. Powers' presentation here:
http://www.webcastmyevent.co.uk/nwbio2015/

Post has attachment
Northwest Biotherapeutics (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax®-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. Read more: http://ow.ly/Rd3Rp

Post has attachment
NW Bio has released promising new data on our Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors. The patients enrolled in the trial had late stage cancers, with an average of three inoperable tumors. The patients had failed multiple prior therapies and had a poor prognosis. The trial enrolled 40 patients, and 39 were evaluable. 86% of Phase I patients treated with preferred method are still alive. Read all about our findings to date in this press release: http://ow.ly/NJx1I

Today at The New York Academy of Sciences' Conference on Emerging Approaches to Immunotherapy, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the scientific basis for the DCVax-Direct technology, and emerging observations from the Phase I/II clinical trial for inoperable solid tumor cancers. Learn more: ow.ly/Nfaqh

Post has attachment
Tomorrow on May 7th at 12:15 ET, NW Bio's CEO, Linda Powers, will present a live overview of the Company's DCVax cancer vaccine platform for solid tumor cancers and the Company's multiple clinical programs at VirtualInvestorConferences.com. We invite individual and institutional investors as well as advisors to attend real-time.

Learn how to register and more in this press release: http://ow.ly/MArWh 

Post has attachment
Today at the American Association for Cancer Research (AACR) Annual Meeting, the Clinical Trial Investigator at MD Anderson Cancer Center will present a poster on the DCVax-Direct program, entitled Clinical and Immunopathological Effects Following Image-Guided Intratumoral Injection Of Activated, Autologous Dendritic Cells In Patients With Advanced Solid Cancers.

The poster will provide information about immune responses in the patients in the Phase I trial overall, as well as case study information. Stop by Section 26 of Halls B–E of the Convention Center, from 1:00 p.m. to 5:00 p.m. to view the presentation.

Check out the full poster here: http://ow.ly/LR5ks

Post has attachment
Today at the American Association for Cancer Research (AACR)​ Annual Meeting in Philadelphia, Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present information about both our DCVax-L and DCVax-Direct clinical programs.
“In line with the theme of this year’s AACR meeting, we look forward to being able to bring DCVax dendritic cell therapies to patients as a potential new treatment option at the forefront of immune therapies for cancer,” commented Linda Powers, CEO of NW Bio.
Learn more in this press release: http://ow.ly/LQpzs

Post has attachment
We're pleased to announce that we are currently ranked 8th in the new Loncar Cancer Immunotherapy Index (LCINDX) of the top 25 cancer immunotherapy companies. We welcome the advent of this new Index, which was established to help investors better track the immunotherapy field within the biotechnology space, and thank them for including us.
Learn more here: http://ow.ly/LGP4K

Post has attachment
NW Bio announced that Leslie J. Goldman, Senior Vice President Business Development, will present today at the World Vaccine Congress 2015 at 10:25am ET. Mr. Goldman will be speaking as part of the co-located Cancer & Immunotherapy conference. During his presentation, he will provide an overview of the Company’s vaccine technology, product pipeline and clinical programs. A live audio webcast will be available and can be accessed on the Company's website. Read the full press release for more information. http://bit.ly/1GsIUC1
Wait while more posts are being loaded